Nanvuranlat - J-Pharma
Alternative Names: JPH-203; JPH-203SBECD; KYT-0353Latest Information Update: 28 Apr 2025
At a glance
- Originator J-Pharma
- Class Amines; Antineoplastics; Benzoxazoles; Chlorobenzenes; Phenyl ethers; Small molecules
- Mechanism of Action Amino acid transport system L inhibitors; Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Biliary cancer
- Phase II Colorectal cancer
- Preclinical Idiopathic pulmonary fibrosis
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Biliary-cancer in USA (IV)
- 31 Dec 2024 No development reported for Biliary cancer in Japan (PO) (J-Pharma pipeline, December 2024)
- 31 Dec 2024 Phase-II clinical trials in Colorectal cancer in USA (IV) (J-Pharma pipeline, December 2024)